Chemclin Diagnostics(SH:688468) Sou Hu Cai Jing·2025-07-28 11:40Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a significant decline in revenue and net profit in the latest quarterly report [1][2] - Kemei Diagnostics' stock closed at 7.99 yuan, with a rolling PE ratio of 31.05, marking a new low in 90 days, and a total market capitalization of 3.205 billion yuan [1] - The company ranks 63rd in the medical device industry, which has an average PE ratio of 55.28 and a median of 38.06 [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company has obtained 64 new domestic and international patents during the reporting period, showcasing its growing innovation capability and technological reserves [1] Group 3 - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]